石药(01093.HK)抗体药物偶联物产品获批内地展开临床

阿斯达克财经
07 Jan

石药集团(01093.HK) 公布,其开发的SYS 6045(抗体药物偶联物)已获国家药品监督管理局批准,可以在内地开展临床试验。公司指,产品为一款单克隆抗体药物偶联物,通过内吞作用进入细胞并释放毒素,达到杀伤肿瘤细胞的作用。产品预计适用于治疗乳腺癌及胃癌等不同癌症。(vc/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-07 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10